

Table S1. Characteristics of patients with appropriate WCD shocks.

Sex	Age	WCD Indication	LVEF at baseline	Days till WCD shock	Type of arrhythmia	WCD Shock successful	ICD implant.	Death during 3 yr follow up	Arrythmia during Follow up/ type of arrhythmia	ICD shocks
male	66	ICM	35	62	VT	yes	yes	no	VT	yes
female	31	Myocarditis	53	37	VT	yes	yes	no	no	
male	48	ICD-Explant. (ICM)	30	56	VT	yes	yes	no	no	
male	53	ICM	25	2	VF	yes	yes	no	no	
male	64	ICM	35	64	VT	yes	yes	no	VT	yes
male	75	ICM	20	151	VT	yes	yes	no	no	

WCD= wearable cardioverter-defibrillator, ICD= implanted cardioverter-defibrillator, LVEF = left ventricular function (%), VT= ventricular tachycardia;

VF= ventricular fibrillation, ICM = ischemic cardiomyopathy, NICM = non-ischemic cardiomyopathy

Table S2. Characteristics of patients with appropriate ICD shocks.

Sex	Age	Indication WCD	LVEF at baseline	improved LVEF after 6-12 months (>35%)	Shock while WCD	Type of arrhythmia	ICD shocks	Death during follow up
M	66	ICM	35	yes	yes	VT	y	n
M	63	ICM	30	no	no	VT	y	n
M	79	ICM	25	no	no	VT	y	n
M	54	NICM/Myocarditis	15	yes	no	VT	n	n
M	65	NICM	25	yes	no	VT	y	n
M	64	ICM	35	unknown	yes	VT	y	n
M	65	ICM	35	no	no	VT	y	n
M	74	ICD-Explant.	30	no	no	VT	y	n

WCD= wearable cardioverter-defibrillator; LVEF = left ventricular function (%); ICD= implanted cardioverter-defibrillator;

ICM = ischemic cardiomyopathy, NICM = non-ischemic cardiomyopathy; VT= ventricular tachycardia.

**Table S3.** Characteristics and variables of patients and frequencies for death.

<b>Variables</b>	<b>death, n = 15</b>	<b>no death, n = 134</b>
Age in years, mean $\pm$ SD	71 $\pm$ 12	59 $\pm$ 13
Male, n (%)	11 (73)	105 (78)
WCD wear days, mean $\pm$ SD	40 $\pm$ 26	68 $\pm$ 43
Former significant VT/VF* event prior to WCD* use	6 (40)	19 (14)
Arrhythmic episodes during WCD use, n (%)	0 (0)	6 (4)
LGE*, n (%)	2 (13)	57 (43)
LVEF* at baseline, mean $\pm$ SD	29 $\pm$ 14	29 $\pm$ 10
Elevated BNP at baseline, mean $\pm$ SD	7461 $\pm$ 6074	7778 $\pm$ 28160
QRS at baseline, mean $\pm$ SD	138 $\pm$ 42	107 $\pm$ 28
QTc at baseline, mean $\pm$ SD	480 $\pm$ 48	458 $\pm$ 56
PQ-time at baseline, mean $\pm$ SD	168 $\pm$ 16	165 $\pm$ 27
History of CAD*, n (%)	10 (67)	51 (38)
Dialysis as comorbidity, n (%)	6 (40)	14 (10)
Risk factor Diabetes, n (%)	7 (47)	24 (18)
Risk factor Hypertension, n (%)	12 (80)	72 (54)
Risk factor Active smoker, n (%)	4 (27)	61 (46)
Risk factor Lipidemia, n (%)	11 (73)	55 (41)
Risk factor Overweight, n (%)	9 (60)	95 (71)
Family history of CVD*, n (%)	1 (7)	40 (30)
ACE* inhibitors, n (%)	14 (93)	117 (87)
Aldosterone antagonists, n (%)t	7 (47)	78 (58)
Betablockers, n (%)	15 (100)	128 (96)

\*VT, ventricular tachycardia; VF, ventricular fibrillation; WCD, wearable cardioverter defibrillator; LGE, late gadolinium enhancement; LVEF, left ventricular ejection fraction; CAD, cardiac artery disease; CVD, cardiovascular disease; ACE, angiotensin converting enzyme

**Table S4.** Characteristics and variables of patients and frequencies for shocks.

	<b>Patients with shocks, n = 8</b>	<b>Patients without shocks, n = 54</b>
Age in years, mean $\pm$ SD	67 $\pm$ 7	60 $\pm$ 14
Male, n (%)	8 (100)	41 (76)
WCD wear days, mean $\pm$ SD	63 $\pm$ 32	65 $\pm$ 41
Former significant VT/VF* event prior to WCD* use	1 (13)	12 (22)
Arrhythmic episodes during WCD use, n (%)	2 (25)	4 (7)
LGE*, n (%)	5 (63)	16 (30)
LVEF* at baseline, mean $\pm$ SD	29 $\pm$ 7	29 $\pm$ 11
Elevated BNP at baseline, mean $\pm$ SD	4001 $\pm$ 2628	8264 $\pm$ 28892
QRS at baseline, mean $\pm$ SD	117 $\pm$ 35	108 $\pm$ 30
QTc at baseline, mean $\pm$ SD	405 $\pm$ 141	462 $\pm$ 44
PQ-time at baseline, mean $\pm$ SD	176 $\pm$ 30	164 $\pm$ 26
History of CAD*, n (%)	5 (63)	26 (48)
Dialysis as comorbidity, n (%)	2 (25)	8 (15)
Risk factor Diabetes, n (%)	1 (13)	12 (22)
Risk factor Hypertension, n (%)	6 (75)	36 (67)
Risk factor Active smoker, n (%)	6 (75)	23 (43)
Risk factor Lipidemia, n (%)	6 (75)	31 (57)
Risk factor Overweight, n (%)	5 (63)	36 (67)
Family history of CVD*, n (%)	1 (13)	13 (24)
ACE* inhibitors, n (%)	8 (100)	45 (83)
Aldosterone antagonists, n (%)t	3 (38)	33 (61)
Betablockers, n (%)	8 (100)	53 (98)